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Nucleosome position, density, and post-translational
modification are widely accepted components of
mechanisms regulating DNA transcription but still
incompletely understood. We present a modified
native ChIP-seq method combined with an analytical
framework that allows MNase accessibility to be
integrated with histone modification profiles. Appli-
cation of this methodology to the primitive (CD34+)
subset of normal human cord blood cells enabled
genomic regions enriched in one versus two nucleo-
somes marked by histone 3 lysine 4 trimethylation
(H3K4me3) and/or histone 3 lysine 27 trimethylation
(H3K27me3) to be associated with their transcrip-
tional andDNAmethylation states. From this analysis,
we defined four classes of promoter-specific profiles
and demonstrated that a majority of bivalent marked
promoters are heterogeneously marked at a single-
cell level in thisprimitivecell type. Interestingly, exten-
sion of this approach to human embryonic stem cells
revealed an altered relationship between chromatin
modification state and nucleosome content at pro-
moters, suggesting developmental stage-specific
organization of histone methylation states.INTRODUCTION
The eukaryotic genome is packaged into chromatin via repeating
nucleosome structures. Each of these consists of two copies of
four histone proteins (H2A, H2B, H3, and H4) associated with
146 base pairs (bp) of DNA (Kornberg and Lorch, 1999; Simp-
son, 1991). Nucleosome position is tightly controlled within
gene promoter boundaries by nucleosome remodeling com-
plexes, thereby contributing to the regulation of gene expression
by altering accessibility of the DNA to transcription factors and2112 Cell Reports 17, 2112–2124, November 15, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://the RNA polymerase machinery (Schones et al., 2008; Segal
et al., 2006; Li et al., 2014b).
Histones within the nucleosome complex are subjected to
different types of covalent chemical modifications (Li et al.,
2014a; Allfrey et al., 1964). These chemical modifications
include acetylation, methylation, phosphorylation, ubiquityla-
tion, sumoylation, formylation, and hydroxylation of specific his-
tone amino acids (Kouzarides, 2002; Jiang et al., 2007, 2012;
Wang et al., 2001; Weake and Workman, 2008; Shiio and
Eisenman, 2003). The spectrum of these histone modifications
present in different regions establishes chromatin states that,
in turn, control access of molecular complexes that allow
transcriptional activation (Kundaje et al., 2015; ENCODE Project
Consortium, 2012; Jenuwein and Allis, 2001). Histone modifi-
cations can occur as single alterations (Allfrey et al., 1964), but
multiple modifications have also been found on the tail of a single
histone molecule (Bernstein et al., 2006; Matsumura et al., 2015;
Sachs et al., 2013). One example of co-occurring histone
modifications is the combination of histone 3 lysine 27 tri-
methylation (H3K27me3) and histone 3 lysine 4 trimethylation
(H3K4me3) at promoters of genes associated with developmen-
tally important genes in embryonic stem cells (ESCs) (Bernstein
et al., 2006; Voigt et al., 2013), most of which (75%) become
monovalent in their differentiated progeny (Mikkelsen et al.,
2007). However, bivalency is not a unique feature of ESCs
because this state has also been identified in chromatin immuno-
precipitation sequencing (ChIP-seq) profiles of other cell types
(Mikkelsen et al., 2007; Kundaje et al., 2015). In addition, sophis-
ticated cell sorting and single-molecule imaging techniques have
indicated that at least a portion of bivalent promoters identified in
populations of cells by ChIP-seq are monovalent in different
component cell subsets (Shema et al., 2016; Hong et al.,
2011). However, the extent to which such heterogeneity in
histone modifications of promoter nucleosomes exists at the
single-cell level remains generally unknown, and the range of
functional consequences of variability in promoter nucleosome
modification also remains undefined.
DNA methylation can be both associated with and mutually
exclusive to specific histone modifications. For example, DNAuthors.
creativecommons.org/licenses/by-nc-nd/4.0/).
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methylation is not found on genomic regions marked by
H3K4me3 (Ooi et al., 2007). On the other hand, de novo methyl-
ation is preferentially targeted to genomic regions with elevated
histone 3 lysine 36 trimethylation (H3K36me3) levels (Baubec
et al., 2015). The relationship between DNA methylation and
H3K27me3 is complex and not fully understood. Direct inter-
action of the catalytic subunit of the PRC2 complex, EZH2 with
DNMT3A, has been reported (Rush et al., 2009), as has the
recruitment of this complex to H3K27me3-marked promoters
in the absence of DNA methylation (Jermann et al., 2014).
More recently, epigenomic profiles of a collection of primary hu-
man cell types revealed H3K27me3-enriched chromatin states
associated with both hyper- and hypomethylated DNA, suggest-
ing that additional factors contribute to the methylation state of
H3K27me3-marked regions of DNA (Kundaje et al., 2015).
Given that both nucleosome density and histone modifica-
tions play a role in the local control of gene transcription, we
sought here to investigate the relationship between bivalent his-
tone modifications and nucleosome density by utilizing a native
ChIP approach. Integration of nucleosome accessibility with
histone modification states in human ESCs and primitive he-
matopoietic cells allowed bivalent and heterogeneously marked
promoters to be effectively segregated genome-wide and
showed that they belonged to distinct cell types.
RESULTS
Immunoprecipitated DNA Fragment Sizes Correlate
with Different Patterns of Histone Modification
ChIP-seq has emerged as the gold standard for profiling histone
modifications genome-wide. We modified aspects of previ-
ously described ChIP-seq protocols to combine micrococcal
nuclease (MNase) accessibility with histone modification profiles
of reduced numbers of purified subsets of primary human cell
types (Maunakea et al., 2010; Brind’Amour et al., 2015; Barski
et al., 2007). This protocol utilizes MNase digestion to digest
DNA preferentially between nucleosomes (Noll and Kornberg,
1977), thereby producing nucleosome-enriched fragments of
chromatin that can be leveraged by an analytical framework
that exploits their size distributions (Supplemental Experimental
Procedures). We first optimized the MNase treatment of purified
CD34+ cells isolated from pooled normal human cord blood
samples to produce a DNA fragment size distribution profile
anticipated to predominantly contain DNA fragments associated
with single nucleosomes (Figure S1A; 146–150 bp). We then per-
formed immunoprecipitation on this MNase-digested chromatinFigure 1. MNase Accessibility Is Chromatin State Dependent
(A and B) Shift in H3K27me3 (A) and H3K4me3 (B) fragment sizes (DNA fragment
digested chromatin from human CD34+ cord blood cells.
(C) CEEHRC-generated ChromHMM chromatin state definitions and histone ma
(D) and H3K4me3 and input (green).
(E) DNA fragment size distributions at ChromHMM-derived chromatin states in C
(F) Ratio of a single (pink) and two (red) nucleosomes marked with H3K27me3 at
(G) Ratio of a single (dark green) and two (green) nucleosomes marked with H3K
(H) Genome-wide densities of DNA fragments containing one or two nucleosome
(I) Genome-wide densities of DNA fragments containing one or two nucleosome
See also Figures S1 and S2 and Table S1.
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selected for profiling by the International Human Epigenome
Consortium (IHEC) (Supplemental Experimental Procedures).
This revealed a histone modification-associated shift in the sizes
of the DNA fragments (Figures 1A and 1B; single nucleosome
peak at 270 bp because of the addition of adaptors required
for sequencing) not previously observed in DNA immunopre-
cipitated from formaldehyde-cross-linked chromatin (data not
shown). We then sequenced the resulting libraries according to
IHEC recommendations (Supplemental Experimental Proced-
ures). Comparison of the results with a ChIP-seq dataset ob-
tained from a different, larger pool (106 cells) of similarly isolated
and analyzed normal human CD34+ cord blood cells (generated
by theCanadian Epigenetics, Environment, andHealth Research
Consortium [CEEHRC]) showed a significant correlation be-
tween the native and reference epigenome ChIP-seq tracks
across all five marks (average Spearman rho = 0.80; Figures
S1B–S1D; Table S1). Correlating immunoprecipitated frag-
ment size, determined by paired-end read boundaries, with
ChromHMM-derived chromatin states derived from these cell
types (Ernst and Kellis, 2012) revealed unique fragment size
profiles for each type of histone modification (Figures 1C–1E;
Figure S2A). H3K27me3, H3K36me3, H3K4me3, and histone 3
lysine 9 trimethylation (H3K9me3) profiles showed chromatin
state-specific fragment length distributions for each profile (Fig-
ure S2A), whereas the distribution of fragments with histone 3
lysine 4 monomethylation (H3K4me1) remained consistent
across all chromatin states (Figure S2A). When observed, the
chromatin state-specific fragment lengths were enriched in re-
gions with high signal-to-noise ratios (and were thus selected
for inclusion in the ChromHMM model). In contrast, genome-
wide distributions were dominated by the input fragment length
distribution regardless of the histone modification present (Fig-
ure S2B). The variable distribution of fragment sizes associated
with specific chromatin states was not evident in the CEEHRC
CD34+ cord blood cell dataset derived from formaldehyde
cross-linked and sonicated ChIP-seq (Figures S2C and S2D).
Nucleosome Density ChIP-Seq Classifies Promoters
Based on Nucleosome Density
To explore the functional implications of observed differences in
immunoprecipitated fragment sizes, we next focused on pro-
moter regions in the CD34+ cord blood cell ChIP-seq data. We
first analyzed the distribution of H3K4me3 andH3K27me3marks
in fragments identified by their size as enriched in either one
(100–220 bp) or two (280–600 bp) nucleosomes within regions+ sequencing adaptor of 125bp) before (blue) and following IP (red) of MNase-
rk probabilities in CD34+ cord blood cells. H3K27me3 and input (red).
D34+ cord blood cells.
gene promoters.
4me3 at gene promoters.
s marked with H3K27me3 (left) and at promoters (right).
s marked with H3K4me3 (left) and at promoters (right).
identified as enriched by MACS2 (Feng et al., 2012; Figures S2E
and S2F). This analysis revealed a negative correlation between
the inferred ratios of fragments associated with one or two nucle-
osomes selectively at H3K4me3- and H3K27me3-marked pro-
moters (Figures 1F and 1G). This finding suggests that MNase
accessibility is stable and regionally specific and, hence, likely
to reflect variations in nucleosome density associated with
specifically modified nucleosomes. We also found a majority of
H3K27me3-marked promoters to be dominated by DNA frag-
ment sizes, indicative of the presence of two nucleosomes (Fig-
ure 1H). In contrast, we found H3K4me3-marked promoters to
be dominated by fragment sizes expected to contain a single
nucleosome (Figure 1I).
To examine these relationships at all promoters, we consid-
ered the fragment distribution to be a mixture of two indepen-
dent Gaussian distributions predicted for DNA fragments associ-
ated with one (mean length of 150 bp) or two nucleosomes
(mean length of 320 bp) (Figure 2A). A weighted value was
assigned to each distribution based on the following formula:
w1  nðx; m1; s1Þ+w2  nðx; m2; s2Þ= 1, where w1 and w2 repre-
sent the contributions of the one-nucleosome and two-nucleo-
some fragment distributions, respectively (Verbeek et al., 2003;
Fraley and Raftery, 1999, 2002). We then assigned promoters
as predominantly associated with one or two nucleosomes
based on their prevalence in the total distribution (cutoff at
w > 0.6). Mixed promoters with w values between 0.5 and 0.6
for either single or two nucleosome-associated fragment distri-
butions were excluded from subsequent analysis.
A Majority of Bivalent Promoters in CD34+ Cord Blood
Cells Identified by Nucleosome Density ChIP-Seq Are
Heterogeneous
Promoters identified as marked by both H3K4me3 and
H3K27me3 were originally found in ESCs but have since been
described in a variety of progenitor and differentiated cell popu-
lations (Kundaje et al., 2015). However, the degree to which such
bivalent patterns reflect variations in histone modifications in
different cells within the population analyzed (cellular heteroge-
neity) has not generally been examined (Shema et al., 2016;
Brookes et al., 2012). We reasoned that the extent to which
bivalent states are indicative of H3K27me3 and H3K4me3marks
on the same nucleosomes would be reflected in the similarity
of the distributions of fragments obtained from dually labeled
chromatin immunoprecipitates (Figure 2B). Examination of
H3K4me3 and H3K27me3 fragment distributions at bivalently
marked promoters in our CD34+ cord blood data revealed distri-
butions that differed significantly (Kolmogorov-Smirnov p value <
3.44 3 1012; Figure 2C). This finding suggests that most of the
promoters in this population identified as bivalent reflect differ-
ences in the marks present in individual cells in the population,
with promoters in any given single cell marked by only one of
the two histone modifications.
Toundertakeabroader examinationofbivalentpromoters inour
dataset, we classified all apparently marked (H3K4me3- and/or
H3K27me3-enriched) promoters into four states: a transcrip-
tionally active state in which either one or two nucleosomes are
markedbyH3K4me3 (Figure 3A), a repressive state inwhich either
one or two nucleosomes are marked by H3K27me3 (Figure 3B), aheterogeneous state consisting of one nucleosome marked by
H3K4me3 and two nucleosomes marked by H3K27me3 (Fig-
ure 3C), and a bivalent state in which two nucleosomes are
present and marked by H3K4me3 and H3K27me3 (Figure 3D).
The w values obtained within promoters correlated well be-
tween the replicates, and the degree of overlap in promoters
defined as having single nucleosomes in one replicate and two
in another replicatewas not significant (Figures 3E and 3F; Figures
S3A–S3C).
Heterogeneous states, defined as likely containing different
fragment lengths forH3K4me3andH3K27me3marks,were found
predominantly at promoters (e.g., for FOXC1). A smaller, but
nevertheless significant, set of promoters was found to be in a
bivalent state andassociatedwith similar fragment lengthdistribu-
tions for both marks (e.g., ETV7). We did not identify any gene
promoters containing two nucleosomes marked by H3K4me3
and also containing a single H3K27me3-marked nucleosome.
On average, only six gene promoters per replicate contained sin-
gle nucleosome-sized fragments marked by both H3K4me3 and
H3K27me3 (Figure 3G, left, bivalent single nucleosome). A major-
ity of promoters marked with both H3K4me3 and H3K27me3
(>60%across all replicates) appeared to be associatedwith a sin-
gle nucleosome marked by H3K4me3 or, alternatively, with two
nucleosomes marked by H3K27me3 (Figure 3G, left, heteroge-
neous). Gene enrichment (McLean et al., 2010) analysis of the
genes associated with heterogeneous promoter profiles revealed
that theyweregenerally associatedwith genes related todevelop-
ment and stem cell differentiation (Figure S4). Among those asso-
ciated with promoters identified here as bivalent (containing two
nucleosomes marked simultaneously by both H3K4me3 and
H3K27me3,onaverage270acrossall replicates, geneenrichment
corrected p value of < 3.93 1017) were genes for key transcrip-
tion factors implicated in hematopoietic cell differentiation and
self-renewal. These included GATA3 (Frelin et al., 2013), CEBPA
(Rebel et al., 2002),EBF2 (Kieslingeret al., 2010), and theETS tran-
scription factor ETV7 (Geltink and Grosveld, 2013).
As a test of our classifications, we performed an experiment in
which MNase-treated CD34+ cord blood cell chromatin was
subjected first to ChIP with H3K4me3 followed by H3K27me3
and the inverse (Experimental Procedures). As predicted by
our nucleosome density ChIP-seq (ndChIP-seq) classifications,
the results showed enrichment at the ETV7 (bivalent) promoter
but not at the (heterogeneous) FOXC1 promoter (Figure 3H).
To assess the ndChIP-seq classification of heterogeneous and
bivalent promoters genome-wide, we compared H3K4me3 and
H3K27me3 signals at identified bivalent and heterogeneous
promoters with that of sequential immunoprecipitation (IP) sig-
nals (H3K4me3 followed by H3K27me3 and vice versa) (Fig-
ure S3D). The results from H3K4me3 and H3K27me3 IPs corre-
lated (Pearson; 0.775 and 0.323, respectively) with sequential
IPs at ndChIP-seq-classified bivalent promoters, indicating
that this signal is maintained after a second IP. In contrast,
low or negative correlations were observed between H3K4me3
and H3K27me3 IPs (Pearson; 0.198 and 0.026, respectively)
and sequential IPs at ndChIP-seq-classified heterogeneous
promoters.
NdChIP-seq analysis thus shows that a majority of bivalently
marked promoters in individual human CD34+ cord blood cellsCell Reports 17, 2112–2124, November 15, 2016 2115
Figure 2. NdChIP-Seq Identifies Heterogeneously Marked Promoters in Individual Cells within Bulk Populations
(A) Schematic of the process of assigning one or two nucleosome-dominated promoters. A Gaussian mixture distribution model was used to determine the
contributions of DNA fragment sizes to the total fragment distribution expected from one and two nucleosomes at each enriched promoter.
(B) Distinguishing between bivalent and heterogeneous chromatin states based on immunoprecipitated DNA fragment length distributions fromMNase digested
chromatin.
(C) H3K4me3 (green) and H3K27me3 (red) immunoprecipitated and input (blue) fragment distributions at co-marked promoters.
See also Figure S2.
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are associated with nucleosomes that are separately marked
either by H3K4me3 or H3K27me3. In addition, these also contain
a small subset of promoters that are predicted to be bivalent at
the single-cell level and control genes encoding factors impli-
cated in hematopoietic development.
MNase Accessibility and Histone Modification Status
Are Associated with RNA Expression
To further investigate the functional significance of combining
nucleosome accessibility and histone modification profiles in
CD34+ human cord blood cells, we correlated the ndChIP-seq
states identified with RNA sequencing (RNA-seq) data for the
same cells (Supplemental Experimental Procedures). Strikingly,
we found that each class of promoter exhibited a unique rela-
tionship with RNA expression (Figure 3G, center). As expected,
active states characterized by H3K4me3 on single nucleosomes
correlated with active transcription of associated genes. Pro-
moters enriched in two H3K4me3-marked nucleosomes were
also found to be associated with active genes, but transcription
levels from the latter were significantly lower than for genes
with promoters enriched in single H3K4me3-marked nucleo-
somes (two-sided t test, p value = 0.003). These results support
a model where changes in MNase accessibility in combination
with changes in histone modification contribute to the control
of gene expression (Jin et al., 2015).
As expected, promoters marked by H3K27me3, regardless of
their MNase accessibility, were associated with low levels of
expression of the genes they regulate. However, we noted that
promoters with single H3K27me3-marked nucleosomes were
associated with significantly reduced expression of their down-
stream genes compared with genes whose promoters appeared
to be enriched in their content of two H3K27me3-marked nucle-
osomes (two-sided t test, p value = 1.73 105). Genes with pro-
moters identified as heterogeneous showed intermediate levels
of expression relative to active and repressed genes, possibly re-
flecting the known biological heterogeneity of cell types within
the CD34+ cord blood compartment. Promoters classified as
bivalent (Figure 3G, bivalent two-nucleosome) showed similar
levels of expression of their downstream genes compared with
two H3K27me3-marked nucleosomes promoters (two-sided
t test, p value 0.231). Genes associated with bivalent promoters
were also found to be significantly repressed compared with
heterogeneously marked promoters (two-sided t test, p value =
0.005), further supporting our ndChIP-seq-based classification.Figure 3. Gene Promoters Show Reproducible Fragment Size Distribut
Profiles
(A–D) Fragment length distributions at promoters (defined as +1,000 bp and 300
indicating the TSS) at a two-nucleosome-dominated H3K4me3 promoter (HN1L
heterogeneous promoter (FOXC1) (C), and at a bivalent promoter (ETV7) (D).
(E) Correlation between two nucleosomes in weighted fragment size distribut
CD34+cord blood cells (Pearson correlation of 0.85).
(F) Correlation between w2 of two replicates of H3K4me3 ndChIP-seq profiles fro
(G) Number of each class of promoters identified in human CD34+ cord blood c
moters). Shown is RNA expression distribution at each identified promoter class (
classes (right).
(H) Genome browser shot of ETV7 and FOXC1 promoters. Shown are H3K27me
(cyan), and sequential IP input DNA (black).
See also Figures S3 and S4.
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between H3K27me3 and CpG Methylation States
Next, we assessed CpG methylation at promoters identified as
enriched in their content of H3K4me3- and H3K27me3-marked
nucleosomes. As expected (Kundaje et al., 2015), a majority of
promoters and classes were found to be in a hypomethylated
state (Figure 3G, right). In agreement with previous reports
(Neri et al., 2013), bivalent promoters were found to be hypo-
methylated (median fractional methylation < 0.2). However,
promoters enriched in their content of a single H3K27me3-
marked nucleosome were found to be hypermethylated (me-
dian fractional methylation > 0.8), and promoters enriched in
their content of two H3K27me3-marked nucleosomes were
hypomethylated.
Promoter MNase Accessibility Profiles Show Cell Type
Differences
Next, we applied our ndChIP-seq protocol to two well character-
ized human ESC lines (H1 and H9) (Meissner, 2010; Hong et al.,
2011). The results again showed a modification-dependent frag-
ment length distribution shift following IP of fragments containing
H3K27me3 and/or H3K4me3, indicative of an enrichment of DNA
fragments associatedwith one or two nucleosomes in these cells
(Figures S5A and S5B). However, in contrast to human CD34+
cord blood cells, the ESC results did not show enrichment for
two-nucleosome fragment sizes at bivalent promoters for
H3K27me3 across the six replicates tested (Figures 4A–4C).
Rather, the ESC promoter distributions were dominated by
single-nucleosome-length fragments for both H3K4me3 and
H3K27me3, perhaps reflective of a more generally open chro-
matin structure than may be present in more restricted cell
types (West et al., 2014). Analysis of the ESC nucleosome frag-
ment size distributions also showed that the majority (>80%) of
promoters containing H3K4me3- andH3K27me3-marked nucle-
osomes were present together on single nucleosomes and,
hence, reflective of a bivalent state at the single-cell level (Fig-
ures 4D and S5C, left; Shema et al., 2016). Input size distribu-
tions (Figure S5D) and the number of two-nucleosome
H3K4me3-marked promoters were similar in the CD34+ cord
blood and human ESC (hESC) datasets (average of 302 and
240 promoters across all replicates, respectively), arguing
against differences in MNase digestion.
ESCs, like CD34+ cord blood cells, showed levels of expres-
sion of genes with bivalent promoters that were significantlyions Associated with Distinct RNA Expression and DNA Methylation
bp from the transcriptional start site [TSS], shown as a circle with a black line
) (A), at a one-nucleosome-dominated H3K27me3 promoter (APOH) (B), at a
ions (w2) of two replicates of H3K27me3 ndChIP-seq profiles from human
m human CD34+ cord blood cells (Pearson correlation of 0.83).
ells (left). * indicates an insignificant number of promoters (less than ten pro-
center). Also shown is fractional DNA methylation distribution across promoter
3 (red), H3K4me3 (green), H3K27me3-H3K4me3 (blue), H3K4me3-H3K27me3
Figure 4. Modified Promoters in ESCs Show Distinct Patterns of MNase Accessibility
(A–C) H3K4me3 (green) and H3K27me3 (red) immunoprecipitated fragment distributions at co-marked promoters in human CD34+ cord blood cells (A) and
human H1 (B) and H9 (C) ESCs.
(D) Number of promoters identified in each class of promoters identified in human H1 ESCs (left). * indicates less than ten promoters. Shown is RNA expression
distribution at each identified promoter class (center). Also shown is fractional DNA methylation distribution across promoter classes (right).
See also Figure S5.lower than those with promoters marked by a single H3K4me3-
modified nucleosome (two-sided t test, p value < 7.3 3 1017).
On the other hand, in ESCs, genes associated to bivalent pro-
moters had expression levels similar to genes associated with
promoters containing two H3K4me3-marked nucleosomes
(two-sided t test, p value = 0.235) (Figures 4D and S5C, center).
In contrast, in cord blood CD34+ cells, this similarity was asso-
ciated with promoters with two H3K27me3-marked nucleo-
somes (two-sided t test, p value = 0.231) (Figure 3G, center).
These results extend to ESCs of human origin the finding that
bivalent promoters are prominent features in this cell type (Bern-stein et al., 2006; Hong et al., 2011), where they are generally
more accessible to MNase digestion than promoters associated
with bivalency in CD34+ cord blood cells.
Human CD34+ Cord Blood Cells and ESCs Exhibit
Different MNase Accessibility at CpG Island-Containing
Promoters
Examination of the relationship between H3K27me3-marked
promoters and CpG methylation in ESCs revealed a reciprocal
bimodal relationship to that seen in human CD34+ cord blood
cells (Figures 4D and S5C, right). Thus, in ESCs, promotersCell Reports 17, 2112–2124, November 15, 2016 2119
Figure 5. H3K27me3-Enriched Promoters in Human ESCs and CD34+ Cord Blood Cells Show Reciprocal MNase Accessibility Profiles
(A) Fraction of H3K27me3-enriched promoters associated with one or two nucleosomes containing CpG islands in human ESCs and CD34+ cord blood cells.
(B) Median fractional DNA methylation at H3K27me3-enriched regions genome-wide and at one- and two- nucleosome promoters in human ESCs and CD34+
cord blood cells.
(C) Median CpG density, defined as the ratio of CpG to the total number of base pairs in a promoter, at two- or one-nucleosome-dominated promoters.
(legend continued on next page)
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with two H3K27me3-marked nucleosomes were enriched in
methylated CpGs, whereas those with predominantly one such
nucleosome were hypomethylated. In addition, we found a
similar reciprocal relationship in ESCs and CD34+ cord blood
cells in CpG island density associated with single and double
H3K27me3-marked nucleosome-containing promoters (ESCs
showing more CpG islands in single H3K27me3-marked nucleo-
some-containing promoters and CD34+ cord blood cells
showing more in double H3K27me3-marked nucleosome-con-
taining promoters; Figure 5A). This raises the possibility that
CpG islands in promoters may influence the nucleosome acces-
sibility of H3K27me3-marked promoters to MNase digestion in a
cell-specific manner.
Comparison of the median methylation levels in all regions
containing H3K27me3-marked nucleosomes in ESCs and cord
blood CD34+ cells (Figure 5B) showed these to be hypermethy-
lated in both cell types, consistent with observations of the
Roadmap Epigenomics Consortium (Kundaje et al., 2015). How-
ever, CpG density was inversely correlated with single nucleo-
some-marked promoters in ESCs and those containing two
nucleosomes in CD34+ cord blood cells (Figure 5C). Assessment
of the fractional methylation levels at H3K27me3 marked pro-
moters lacking CpG islands showed hypermethylation of their
DNA (average fractional methylation = 0.77 across all cell types)
regardless of their nucleosome content (Figure 5D). Two nucleo-
some-dominated H3K27me3-marked CpG Island (CGI)-contain-
ing promoters show a higher median fractional methylation level
compared with that of one nucleosome-dominated promoters
in ESCs (average fractional methylation of 0.60 versus 0.18,
respectively), a relationship not observed in cord blood CD34+
cells (Figure 5D).
Together, these results suggest changes in chromatin struc-
ture with prevalent H3K27me3 marking of nucleosomes at
CpG-rich regions in the earliest stages of human embryo devel-
opment, represented by ESCs, with later acquisition of a more
compacted chromatin structure at CpG-rich H3K27me3-marked
promoters despite their retention of their original DNA methyl-
ation status.
Modeling Chromatin State Differences using
Nucleosome Density Data
By incorporating nucleosome density data as an independent
feature in ChromHMM (Ernst and Kellis, 2012), we generated
chromatin states for human ESCs and CD34+ cord blood
cells that incorporated nucleosome accessibility (Supplemental
Experimental Procedures). We first generated chromatin states
for CD34+ cord blood cells independently and confirmed that
these effectively segregated bivalent and heterogeneous pro-
moters and gave classifications supported by sequential ChIP-
seq data (average concordance = 0.70; Figure 5E). Incorporation
of both ESCs and CD34+ cord blood cells into the model identi-
fied expected and unexpected chromatin states and revealed(D) Median fractional DNAmethylation at one (red) and two (black) H3K27me3-ma
cord blood cells (circle) and ESCs (H1, triangle; H9, square).
(E) ChromHMM nucleosome density states at promoters marked with either H3K
(F) ChromHMM nucleosome density states at promoters marked with either H3K4
(G) Gene enrichment analysis of ChromHMM-derived state 1 (green) and state 3transitions between them (Figure 5F). The expected transition
of a bivalent to a heterogeneous state was seen in 497 bivalent
ESC promoters (state 1; Figure 5F). The inverse relationship
was also observed, where 235 bivalent promoters in CD34+
cord blood cells were identified as heterogeneous in ESCs
(state 3; Figure 5F). Enrichment analysis of genes associated
with state 1 promoters revealed that they were enriched in genes
that regulate embryonic and anatomical structure development
(q value < 2.61 3 1085) (Figure 5G). Conversely, in addition to
general developmental terms, genes associatedwith state 3 pro-
moters were enriched in genes implicated in the regulation of cell
differentiation and lineage commitment (q value < 8.91 3 1035)
(Figure 5G). We also identified a small number of promoters (84,
state 7) that maintained bivalency across ESCs and CD34+ cord
blood cells (no significant gene enrichment found).
DISCUSSION
Complex interactions between transcription factors, epigenetic
modifiers, and chromatin structure regulate gene expression
during development and later enable the sustained production
of short-lived specialized cell types throughout adult life. The
importance of epigenomic regulation in these processes is un-
derscored by accumulating evidence of their perturbation in
the generation of malignant populations (Karnezis et al., 2016;
Wiegand et al., 2010; Wang et al., 2011; Sigauke et al., 2006; Ab-
del-Wahab et al., 2011; Shen et al., 2011). Information about the
roles of different chromatin modifications in controlling patterns
of transcription that specify cell types is also rapidly accruing.
Until recently, our understanding of these combinatorial states
was limited to assessments of DNA and histone modifications
(Bernstein et al., 2006; Kundaje et al., 2015). However, these
fail to distinguish between heterogeneity at the level of cellular
versus individual nucleosomes. Current single-molecule tech-
nologies have attempted to address this issue but still lack
the comprehensiveness required to discriminate differences
genome-wide (Shema et al., 2016).
We now report a robust methodology that overcomes this
barrier and use it to distinguish nucleosome density profiles of
promoters appearing to be associated with histones bivalently
marked with H3K27me3 and H3K4me3 modifications as associ-
ated or not with the same promoters in individual cells. Interest-
ingly, in CD34+ cord blood cells, <40% of bivalent promoters
were bivalent at a single-cell level, whereas the corresponding
value in hESCs was >80%. These observations provide impor-
tant evidence of variability in the cell-type- and promoter-
specific sources of heterogeneity, contributing to the profile of
bivalent histones detected from ChIP-seq data obtained from
bulk cell analyses.
Our study also provides insights into the effect of nucleosome
density and chromatin structure on gene expression and DNA
methylation. Classification of promoters based on the densityrked nucleosomeCpG islands and non-CpG island promoters in humanCD34+
4me3 or H3K27me3 in human CD34+ cord blood cells.
me3 and H3K27me3 in human CD34+ cord blood and ESCs (H1 and H9 cells).
(orange).
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and modification of their associated nucleosomes into four
major groups (active, repressed, heterogeneous, and bivalent)
revealed corresponding unique cell-type-specific gene expres-
sion and DNA methylation profiles. We observed a negative cor-
relation between promoter DNA methylation and H3K27me3 at
CGIs, andmethylated promoters containing H3K27me3-marked
nucleosomes lack CpG islands. These findings suggest the exis-
tence of protective protein complexes that prevent DNA methyl-
ation and assist in H3K27me3 deposition on nucleosomes at
CpG island-containing promoters (Jermann et al., 2014; Boulard
et al., 2015; Wu et al., 2013). An example of such a protein is
FBXL10, which prevents DNA methylation at CpG-dense
PRC2-bound regions (Boulard et al., 2015).
Finally, our analysis has revealed a more compact chromatin
structure at CpG islands marked by H3K27me3 in human
CD34+ cord blood cells compared with ESCs. In contrast,
DNA methylation at these promoters is conserved, suggesting
that the dynamic changes in histone modification and chromatin
structure that accompany development stand in contrast to a
much greater stability of DNA methylation (Sørensen et al.,
2010; Herlofsen et al., 2013). The dynamic change of nucleo-
some density observed in H3K27me3-enriched regions between
human CD34+ cord blood cells and ESCs may be explained
by differential expression and engagement of linker histone H1
variants during development and differentiation (Terme et al.,
2011). In support of this model, we find H1X, a replication-inde-
pendent H1 variant, to be upregulated 5-fold in CD34+ cord
blood cells compared with ESCs (reads per kilobase of transcript
per million mapped reads [RPKM] of 583 versus 117). Given the
role of H3K27me3 in regulating crucial genes in early develop-
ment, and the unique content of chromatin remodelers and
H3K27me3 binding proteins in human ESCs (Boyer et al.,
2006; Agger et al., 2007), their DNA may be more accessible to
MNase digestion than derivative tissue cell types.
In summary, we present a methodology that now makes
possible the identification and resolution of histone modifica-
tions at a single-cell resolution, thereby enabling insights into
cell-type-specific mechanisms that regulate the unique tran-
scriptomes of cell populations previously inaccessible to such
analyses.
EXPERIMENTAL PROCEDURES
Cell Isolation
Anonymized normal human cord blood cells were obtained with informed con-
sent fromwomen undergoing full-term births according to protocols approved
by the Research Ethics Board of the University of British Columbia and the
Women and Children’s Hospital of British Columbia. CD3-CD11b-CD19-
CD34+ cells were obtained at >95% purity from pooled collections using a
two-step Rosette-Sep plus EasySep human CD34+ selection kit (STEMCELL
Technologies) according to the manufacturer’s protocols. The H1 and H9
cell lines were provided by STEMCELL Technologies. They were cultured in
mTeSR (STEMCELL Technologies) and passaged every 7 days using ReLeSR
(STEMCELL Technologies). The resulting cells were treated with Accutase to
generate single-cell suspensions and then spun at 5003 g for 5min and resus-
pended in lysis buffer for subsequent ChIP-seq experiments.
NdChIP-Seq Methodology
See the Supplemental Experimental Procedures for details. In brief, cells were
lysed and digested by MNase. Immunoprecipitation was performed using vali-2122 Cell Reports 17, 2112–2124, November 15, 2016dated antibodies against H3K4me1, H3K27me3, H3K9me3, H3K4me3, and
H3K36me3. DNA fragments were stripped from histones, purified, and sub-
jected to Illumina library construction by end repair, 30 A-addition, and Illumina
sequencing adaptor ligation and PCR-amplified. Libraries were sequenced on
an IlluminaHiSeq 2500 sequencing platform following themanufacturer’s proto-
cols. Sequence reads were aligned to GRCh37-lite using Burrows-Wheeler
Aligner (BWA) 0.5.7. (Li and Durbin, 2010). Statistically significant enriched re-
gions were identified by MACS2 (Feng et al., 2012), and weighted distributions
of single and two-nucleosome fragment sizes at each promoter were calculated
using the R-statistical package Mclust version 3.0 (Fraley and Raftery, 2002).
ChIP-Seq
Human cord blood CD34+ cell ChIP-seq data were generated as a part of
CEEHRC. Processed datasets are available through http://www.epigenomes.
ca/data-release/ and http://epigenomesportal.ca/ihec/ under accession num-
ber CEMT32. Standard operating procedures for ChIP-seq library construction
are available at http://www.epigenomes.ca/protocols-and-standards or upon
request.
Sequential ChIP-Seq
See the Supplemental Experimental Procedures for details. In brief, 600,000
human CD34+ cord blood cells were digested with MNase and IP performed
as described (see NdChIP-seq Methodology), except that chromatin was
eluted in a solution of 30 mM DTT, 500 mM NaCl, and 0.1% SDS at 37C.
Eluted chromatins were diluted 30-fold, subjected to a second immunoprecip-
itation, and then eluted with standard elution buffer.
Whole-Genome Bisulfite Sequencing
See the Supplemental Experimental Procedures for details. Human cord blood
CD34+ cell whole-genome bisulfite sequencing (WGBS) data were generated
as a part of CEEHRC. Methylation data for H1 ESCs (GSM432685 and
GSM432685) and H9 ESCs (GSM706059, GSM706060, and GSM706061)
were obtained from the Roadmap Epigenomics Consortium (Kundaje et al.,
2015).
RNA-Seq
See the Supplemental Experimental Procedures for details. Human cord blood
CD34+ cell RNA-seq data were generated as a part of CEEHRC. Processed
datasets are available through http://www.epigenomes.ca/data-release/ and
http://epigenomesportal.ca/ihec/ under accession number CEMT32). Stan-
dard operating procedures for RNA-seq library construction are available at
http://www.epigenomes.ca/protocols-and-standards or upon request. RNA-
seq data for H1 (GSM438361) and H9 (GSM706044) were obtained from the
Roadmap Epigenomics Consortium (Kundaje et al., 2015).
Integrative Analysis
MACS2 (Feng et al., 2012) was employed to identify enriched regions with a
false discovery rate (FDR) value of% 0.05 for broad peaks and% 0.01 for nar-
row peaks in ChIP-seq data. Genomic Regions Enrichment of Annotations
Tool (GREAT) version 2.0 was used to annotate enriched biological processes
associated with promoters (McLean et al., 2010). Concordance between
sequential ChIP-seq and ndChIP-seq was calculated at promoters with
sequence read coverage of > 4. ChromHMM (Ernst and Kellis, 2012) was em-
ployed to identify nucleosome density states at promoters marked with
H3K4me3 and/or H3K27me3 across ESCs and human cord blood CD34+
cells. H3K4me3 one-nucleosome and two-nucleosome and H3K27me3 one-
nucleosome and two-nucleosome promoters in H1, H9, and human cord
blood CD34+ cells were treated as separate tracks in the ChromHMM model
(weighted distribution value R 0.65). ChromHMM LearnModel was used to
generate 15 chromatin states across ESCs and human cord blood CD34+
cells. ChromHMM emissions below 0.2 were omitted from further analysis.
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